dorsaVi (ASX: DVL) has taken a significant step toward the next generation of intelligent wearables and robotics with the acquisition of a neuromorphic technology portfolio from researchers at Technion – Israel Institute of Technology, led by Professor Shahar Kvatinsky, a global authority in Processing-in-Memory and adaptive hardware systems.
dorsaVi secures breakthrough neuromorphic technology to power next-generation wearables and robotics
November 12, 2025 Australian Biotech
Latest Video
New Stories
-
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech -
OncoSil announces first UK patient treated with its pancreatic cancer treatment
December 10, 2025 - - Australian Biotech -
Health Department clarifies PBAC plan after confusion over paediatric access to biologics
December 10, 2025 - - Latest News -
If this was the plan, why wasn't it included in the response to questions last week?
December 10, 2025 - - Latest News -
Immutep strikes major licensing deal with Dr. Reddy’s to commercialise novel cancer immunotherapy
December 9, 2025 - - Australian Biotech
